azr-md-001
Small moleculeexperimental
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Aug 27, 2018 (NCT03652051)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06329791 | Phase 3 | May 28, 2024 | Azura Ophthalmics, ORA, Inc. |
| NCT05548491 | Phase 2 | Nov 10, 2022 | Avania, Azura Ophthalmics |
| NCT04391959 | Phase 2 | Jul 31, 2020 | Azura Ophthalmics, University of New South Wales |
| NCT04314362 | Phase 2/Phase 3 (Phase 3) | Jun 2, 2020 | Azura Ophthalmics, University of New South Wales |
| NCT03972501 | Phase 2 | Jun 25, 2019 | Azura Ophthalmics, University of New South Wales |
| NCT03652051 | Phase 2 | Aug 27, 2018 | Azura Ophthalmics, Save Sight Institute, Syneos Health |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Azura Ophthalmics | For profit | 6 | 6 | 2 | 2018 |
| University of New South Wales | Academic/Hospital | 3 | 0 | 2 | 2019 |
| Avania | For profit | 1 | 0 | 1 | 2022 |
| ORA, Inc. | For profit | 1 | 0 | 1 | 2024 |
| Save Sight Institute | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Syneos Health | For profit | 1 | 0 | 1 | 2018 |
6 organizations
Page 1 / 1